Finance analyst: Eli Lilly deals hard blow to Novo Nordisk with new data

US investment banking company and financial analyst Jefferies views data from US pharmaceutical company Eli Lilly's recent studies with tirzepatide up against Danish firm Novo Nordisk's semaglutide as highly convincing. In-house analyst Peter Welford thinks Novo Nordisk's salespeople will have a hard time contesting tirzepatide's superior effect, since the new data comes from a direct comparison study, known as a head-to-head.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly surpasses Novo's golden diabetes drug
For subscribers